An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Arcturus Therapeutics to Attend the Following Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Arcturus Therapeutics (Nasdaq: ARCT) announced its participation in several upcoming investor conferences, highlighting its focus on mRNA medicines and vaccines. Key events include the Citi’s 17th Annual BioPharma Conference on September 6, 2022, and the Wells Fargo Virtual Healthcare Conference on September 9, 2022, among others. The company emphasizes its innovative technologies and diverse pipeline of therapies targeting infectious diseases and rare liver and respiratory conditions.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global, late-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences.
H.C. Wainwright 24th Annual Global Investment Conference (Presentation)
Monday, September 12, 2022 (3:00 p.m. ET)
Baird Global Healthcare Conference (Presentation)
Wednesday, September 14, 2022 (10:15 a.m. ET)
Cantor Global Healthcare Conference (Panel Presentation)
Thursday, September 15, 2022 (2:30 p.m. ET)
Piper Sandler Heartland Summit (Attending)
Wednesday – Thursday, September 21 – 22, 2022
Links will be available under the Investor Relations/Events section of Arcturus’ website.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation. In addition, please connect with us on Twitter and LinkedIn. For more information visit www.ArcturusRx.com.
Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008
ctanzi@kendallir.com
Source: Arcturus Therapeutics Holdings Inc.
FAQ
What investor conferences will Arcturus participate in September 2022?
Arcturus Therapeutics will participate in several conferences, including Citi’s 17th Annual BioPharma Conference on September 6, Wells Fargo Virtual Healthcare Conference on September 9, H.C. Wainwright Global Investment Conference on September 12, and Baird Global Healthcare Conference on September 14.
What is the focus of Arcturus Therapeutics as mentioned in the PR?
Arcturus Therapeutics focuses on developing mRNA medicines and vaccines, specifically targeting infectious diseases and rare liver and respiratory diseases.
When is the H.C. Wainwright Global Investment Conference where Arcturus will present?
The H.C. Wainwright 24th Annual Global Investment Conference presentation is scheduled for September 12, 2022, at 3:00 p.m. ET.
What technologies does Arcturus use for its mRNA medicines?
Arcturus uses LUNAR® lipid-mediated delivery and STARR™ mRNA Technology to develop its mRNA medicines and vaccines.
Where can I find more information about Arcturus Therapeutics investor events?
More information about Arcturus Therapeutics investor events can be found on their website under the Investor Relations/Events section.
